A growing global biopharmaceutical company focused on endrocrine therapy and oncology, in drug discovery, development and commercialization.


Updates from The Motley Fool

Latest updates on Aeterna Zentaris from Fool.com.  The Fool has written over 100 articles on Aeterna Zentaris.
This Week in Biotech

A look back at the biggest stories this week in biotech and what they mean for investors.

This Week in Biotech

A look back at the biggest stories this week in biotech and what they mean for investors.

This Week in Biotech

A weekly roundup of the goings-on in the world of biotech.



Stock Performance

View Interactive AEZS Charts
Sponsored by

Key Data Points

Primary metrics and data points about Aeterna Zentaris.
Current Price: $2.90
Prev Close: $2.75
Open: $2.75
Bid: $2.25
Ask: $3.10
Day's Range: $2.75 - $2.95
52wk Range: $2.35 - $5.59
Volume: 95,824
Avg Vol 167,130
Market Cap: $39M
P/E (ttm): -1.14
EPS (ttm): ($2.41)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Aeterna Zentaris.
CAPS Rating 2 out of 5
 
331 Outperform
14 Underperform
CAPS All Stars
 
31 Outperform
5 Underperform

How do you think Aeterna Zentaris will perform against the market?



You pick for Aeterna Zentaris is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Prof Jürgen Engel, CEO

0% Approve

Based on 0 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Aeterna Zentaris.

A growing global biopharmaceutical company focused on endrocrine therapy and oncology, in drug discovery, development and commercialization.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers